Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAFLD HEROES
NCT03884075Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2019
- Primary completion
- Aug 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Jul 2019; status: recruiting.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03884075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884075.